We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Realizing the of Potential “Bionic” Nanoparticles for Delivery to Live Cells
Product News

Realizing the of Potential “Bionic” Nanoparticles for Delivery to Live Cells

Realizing the of Potential “Bionic” Nanoparticles for Delivery to Live Cells
Product News

Realizing the of Potential “Bionic” Nanoparticles for Delivery to Live Cells


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Realizing the of Potential “Bionic” Nanoparticles for Delivery to Live Cells"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Abcam and SomaServe, a Pharma service and specialist reagent business exploiting PolyNaut® Technology, have announced a partnership to commercialize the cell delivery potential of the polymer-based “bionic”’ nanoparticles, which can carry a range of payloads directly to live cells.

The collaboration will initially focus on the development and global commercialization of a suite of CelLuminate dyes, specifically created to revolutionize live cell imaging by enabling cells to remain functional and viable for up to 14 days. This reduction in toxicity is designed to give users the ability to thoroughly probe and analyze their cells, enabling them to achieve deeper insights and advance their understanding.

Beyond the aim of improving and enhancing live cell imaging, the team will work together to expand the delivery and assay options of the platform, including optimizing its potential in combination with antibodies and other technologies. In addition to the commercial partnership, Abcam has invested in SomaServe’s seed round to help accelerate the development of an innovative market-leading platform for research, diagnostic and therapeutic applications.  


Advertisement